Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RSLS

RSLS - ReShape Lifesciences Inc. Stock Price, Fair Value and News

$3.26+0.15 (+4.82%)
Market Closed

48/100

RSLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

48/100

RSLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.78

Target 3M

$2.83

Target 6M

$2.82

RSLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RSLS Price Action

Last 7 days

11.9%

Last 30 days

-15.2%

Last 90 days

-41.9%

Trailing 12 Months

-99.3%

RSLS RSI Chart

RSLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RSLS Valuation

Market Cap

18.4M

Price/Earnings (Trailing)

-1.22

Price/Sales (Trailing)

1.55

EV/EBITDA

-2.66

Price/Free Cashflow

-3.02

RSLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.78

Target 3M

$2.83

Target 6M

$2.82

RSLS Fundamentals

RSLS Revenue

Revenue (TTM)

11.9M

Rev. Growth (Yr)

236.19%

Rev. Growth (Qtr)

520.41%

RSLS Earnings

Earnings (TTM)

-15.0M

Earnings Growth (Yr)

-1.4K%

Earnings Growth (Qtr)

-2.6K%

RSLS Profitability

Operating Margin

54.28%

EBT Margin

-37.69%

Return on Equity

-593.97%

Return on Assets

-213.27%

Free Cashflow Yield

-33.08%

RSLS Investor Care

Shares Dilution (1Y)

79100.96%

Diluted EPS (TTM)

1.3K

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.2M6.5M11.9M0
20248.3M8.0M8.2M8.0M
202311.1M10.4M9.8M8.7M
202212.8M12.2M11.3M11.2M
202112.7M14.6M14.7M13.6M
20202.3M3.6M6.9M10.3M
20199.5M7.2M4.5M3.3M
20189.8M10.6M10.8M9.1M
20173.8M5.0M7.0M9.9M
20164.2M3.9M3.6M3.4M
20153.6M3.8M3.9M4.0M
20140003.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About ReShape Lifesciences Inc.

RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
 CEO
 WEBSITEreshapelifesciences.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES40

ReShape Lifesciences Inc. Frequently Asked Questions

RSLS is the stock ticker symbol of ReShape Lifesciences Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of ReShape Lifesciences Inc. is 18.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RSLS's fair value in chart for subscribers.

The fair value guage provides a quick view whether RSLS is over valued or under valued. Whether ReShape Lifesciences Inc. is cheap or expensive depends on the assumptions which impact ReShape Lifesciences Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RSLS.

As of Tue Jan 27 2026, RSLS's PE ratio (Price to Earnings) is -1.22 and Price to Sales (PS) ratio is 1.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RSLS PE ratio will change depending on the future growth rate expectations of investors.